search
Back to results

Impact of Vitamin D Supplementation on Recurrent Respiratory Infections in Paediatric Primary Care.

Primary Purpose

Recurrent Respiratory Tract Infections

Status
Completed
Phase
Phase 4
Locations
Study Type
Interventional
Intervention
Vitamin D3
Sponsored by
Policlinico Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Recurrent Respiratory Tract Infections

Eligibility Criteria

6 Months - 3 Years (Child)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • patients diagnosed the seasons before with: ≥ 6 respiratory infections per annum
  • ≥ 1 respiratory infections per month involving the upper airways from September to April
  • ≥ 3 respiratory infections per annum involving the lower airways

Exclusion Criteria:

  • patients with findings suggestive of an immunodeficiency on history and physical examination

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Active Comparator

    No Intervention

    Arm Label

    Vit D

    Control

    Arm Description

    Vitamin D oral supplementation (400 UI/die up to 12 month or 600 UI/die beyond 1 year) from October to March

    Outcomes

    Primary Outcome Measures

    Number of recurrent respiratory tract infections for each months of study
    reduction of the number of respiratory tract infections in children diagnosed with recurrent respiratory tract infections the seasons before

    Secondary Outcome Measures

    Cost assessment in euros according to antibiotics, paediatric visits and vitamin D supplementation
    Secondary objectives was the assessment of Vitamin D supplementation benefits on global socioeconomic burden of recurrent respiratory tract infections in a primary care setting, according to number of visits to the primary care paediatrician and use of antibiotics due to respiratory tract infections.

    Full Information

    First Posted
    November 23, 2015
    Last Updated
    March 18, 2019
    Sponsor
    Policlinico Hospital
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT02617771
    Brief Title
    Impact of Vitamin D Supplementation on Recurrent Respiratory Infections in Paediatric Primary Care.
    Official Title
    Impact of Vitamin D Supplementation on Recurrent Respiratory Infections in Paediatric
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    March 2019
    Overall Recruitment Status
    Completed
    Study Start Date
    October 2014 (undefined)
    Primary Completion Date
    March 2015 (Actual)
    Study Completion Date
    November 2015 (Actual)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Principal Investigator
    Name of the Sponsor
    Policlinico Hospital

    4. Oversight

    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    Up to date, some clinical trial have evaluated the efficacy and safety of Vitamin D supplementation in children with RRI, with no conclusive information. Therefore, the investigators designed a prospective, single-blind, clinical trial to evaluate whether oral supplementation with vitamin D from October to April reduces the global health burden of recurrent respiratory tract infections in a primary care setting. The primary outcome was evaluated if Vitamin D supplementation during autumn and winter can reduce the number of respiratory tract infections in children diagnosed with recurrent respiratory tract infections the seasons before. Secondary objectives was the assessment of Vitamin D supplementation benefits on global socioeconomic burden of recurrent respiratory tract infections in a primary care setting, according to number of visits to the primary care paediatrician and use of antibiotics due to respiratory tract infections.
    Detailed Description
    The University study personnel randomly allocated patients to receive, from October to March, a Vitamin D oral supplementation (400 UI/die up to 12 month or 600 UI/die beyond 1 year) or not. Randomization was performed using a free web-based service that offers random assignment; patients were randomized considering gender and age class (up to 12 months; beyond 1 years). The primary care practitioner was blinded regarding the study group allocation. Inclusion criteria were: a) patients diagnosed the seasons before with: ≥ 6 respiratory infections per annum OR ≥ 1 respiratory infections per month involving the upper airways from September to April OR ≥ 3 respiratory infections per annum involving the lower airways. b) patients with no findings suggestive of an immunodeficiency on history and physical examination. From the recruitment, parents recorded number and type of diagnosed respiratory tract infections, number of ambulatory visits, use of antibiotics and duration of symptoms in a structured diary. Upper Respiratory Tract Infections (URTIs) comprehends diagnosis of acute otitis media, acute rhinosinusitis and acute pharyngotonsillitis. Lower Respiratory Tract Infections (LRTIs) comprehend diagnosis of bronchiolitis and pneumonia. All parents had a close telephone contact to help them in the diary compilation. Adverse events related to the protocol were monitored. Missing data were recovered through the information system of the primary care practitioner. Quantitative data were expressed as mean and standard deviation. To compare the mean between the two groups, Student's t-test for unpaired was used. The frequency of each visits to the pediatricians and use of antibiotics in the two group was calculated and expressed as a percentage. The χ² test was used to compare the percentages between the two groups. For all tests, P-values <0.05 were considered significant. Since Italian National Health System covers all costs for pediatrician visits and antibiotics, cost assessment was made analysing the costs regarding the frequency of each parameters in treated and nontreated group. We considered as direct cost National Health System: Medical examination (20,66 euros for each examination, as provided by the Italian Ministry of Health) and use of Antibiotics (the cost was as in the list of the National Drug Authority).

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Recurrent Respiratory Tract Infections

    7. Study Design

    Primary Purpose
    Prevention
    Study Phase
    Phase 4
    Interventional Study Model
    Parallel Assignment
    Masking
    Outcomes Assessor
    Allocation
    Randomized
    Enrollment
    84 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    Vit D
    Arm Type
    Active Comparator
    Arm Description
    Vitamin D oral supplementation (400 UI/die up to 12 month or 600 UI/die beyond 1 year) from October to March
    Arm Title
    Control
    Arm Type
    No Intervention
    Intervention Type
    Drug
    Intervention Name(s)
    Vitamin D3
    Intervention Description
    from October to March, a Vitamin D oral supplementation (400 UI/die up to 12 month or 600 UI/die beyond 1 year
    Primary Outcome Measure Information:
    Title
    Number of recurrent respiratory tract infections for each months of study
    Description
    reduction of the number of respiratory tract infections in children diagnosed with recurrent respiratory tract infections the seasons before
    Time Frame
    From October 1, 2014, and March 31, 2015, up to 6 months
    Secondary Outcome Measure Information:
    Title
    Cost assessment in euros according to antibiotics, paediatric visits and vitamin D supplementation
    Description
    Secondary objectives was the assessment of Vitamin D supplementation benefits on global socioeconomic burden of recurrent respiratory tract infections in a primary care setting, according to number of visits to the primary care paediatrician and use of antibiotics due to respiratory tract infections.
    Time Frame
    From October 1, 2014, and March 31, 2015, up to 6 months

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    6 Months
    Maximum Age & Unit of Time
    3 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: patients diagnosed the seasons before with: ≥ 6 respiratory infections per annum ≥ 1 respiratory infections per month involving the upper airways from September to April ≥ 3 respiratory infections per annum involving the lower airways Exclusion Criteria: patients with findings suggestive of an immunodeficiency on history and physical examination
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Maria Elisabetta Baldassarre, MD
    Organizational Affiliation
    University of Bari
    Official's Role
    Principal Investigator

    12. IPD Sharing Statement

    Citations:
    PubMed Identifier
    25881523
    Citation
    de Sa Del Fiol F, Barberato-Filho S, Lopes LC, de Cassia Bergamaschi C. Vitamin D and respiratory infections. J Infect Dev Ctries. 2015 Apr 15;9(4):355-61. doi: 10.3855/jidc.5711.
    Results Reference
    background
    PubMed Identifier
    22254030
    Citation
    Zittermann A, Gummert JF. Nonclassical vitamin D action. Nutrients. 2010 Apr;2(4):408-25. doi: 10.3390/nu2040408. Epub 2010 Mar 25.
    Results Reference
    result

    Learn more about this trial

    Impact of Vitamin D Supplementation on Recurrent Respiratory Infections in Paediatric Primary Care.

    We'll reach out to this number within 24 hrs